Use of Statins and Fracture

Douglas C. Bauer, Greg R. Mundy, Sophie A. Jamal, Dennis M. Black, Jane A. Cauley, Kristine E. Ensrud, Marjolein van der Klift, Huibert A. P. Pols
2004 Archives of Internal Medicine  
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used for the treatment of hyperlipidemia, and recent in vitro and animal data suggest that statins promote bone formation and increase bone strength. Methods: To determine whether statin use is associated with a reduced risk for fracture, we analyzed statin use and fracture rates in 4 large prospective studies (the Study of Osteoporotic Fractures, the Fracture Intervention Trial, the Heart and
more » ... Heart and Estrogen/Progestin Replacement Study, and the Rotterdam Study). We searched MEDLINE through January 2002 and abstracts from major scientific meetings and performed a cumulative metaanalysis of published and unpublished observational studies and clinical trials. The meta-analysis included 8 observational studies and 2 clinical trials that reported statin use and documented fracture outcomes. Results: After adjustment for multiple factors, including age, body mass index, and estrogen use, we found a (REPRINTED) ARCH INTERN MED
doi:10.1001/archinte.164.2.146 pmid:14744837 fatcat:pnbbqjkzljetdd7s4mftg4sxqe